o3 Capital acted as the exclusive financial advisor to Sentiss Pharma Pvt. Ltd. on its acquisition of select assets of Akorn Pharma

Sentiss Pharma Pvt. Ltd. (“Sentiss”), a leading Ophthalmic focused formulations player, has acquired select ANDAs of Akorn Operating US and 100% equity of Akorn International S.à r.l along with its wholly owned subsidiary Akorn AG (“Akorn”), a Switzerland-based manufacturer of Ophthalmic and Otic products.

Founded by Deepak Bahri in 1990, Sentiss provides a range of Ophthalmic, Inhalation, ENT and specialty products. They have been a leader in the Ophthalmic segment in the Russian market and have a strong foothold in CIS countries. This acquisition fast-tracks their expansion into the USA, aligning with their vision of having US markets as a pivotal growth pillar.

Akorn is a Switzerland-based manufacturer of Ophthalmic and Otic products with a legacy of more than 35 years. They deliver superior quality products through their state-of-the-art manufacturing facility which has accreditations from US FDA among others.

Deepak Bahri, Founder & Managing Director of Sentiss said, “We are pleased to announce the acquisition as it makes Sentiss one of the largest Ophthalmic players out of India. Sentiss has been a pioneer in the Ophthalmic segment, and we wish to further build on this legacy with diversification into the US market.”

This deal marks o3 Capital's 12th deal closure in the Healthcare & Lifesciences space in the last 18 months. The deal reiterates o3 Capital’s strong credentials in the Healthcare and Lifesciences segment (54 deal closures till date) and our ability to consummate deals in the formulations space within the Lifesciences industry.